You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A Bullet Proof vascular graft to prevent dialysis access cannulation injury

    SBC: Innavasc Medical, Inc.            Topic: 400

    Project Summary Abstract Synthetic arteriovenous grafts AVGs can provide life sustaining vascular access for dialysis patients but are subject to multiple modes of failure and complications related to chronic needle cannulation poor graft identification delayed access and bleeding These graft needle cannulation associated complications translate to millions of dollars in health care expense ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A cell-free, high-throughput screening service for accelerated GPCR ligand discovery

    SBC: KXT BIO INC.            Topic: 300

    PROJECT SUMMARY The proposed Phase I STTR project is a partnership between a biotechnology company KXTbioIncand the University of North Carolina at Chapel Hill to develop an innovative high throughput screening service for identifying new drug candidates that act via G protein coupled receptorsGPCRsThis large protein superfamily has been the most successful source of therapeutic targetsaccounting ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. A cloud-based digital health navigation program for colorectal cancer screening

    SBC: DIGITAL HEALTH NAVIGATION SOLUTIONS, INC.            Topic: 102

    Over 30% of age-eligible Americans fail to receive recommended screening for colorectal cancer (CRC), the second leading cause of cancer death in the United States. Multilevel barriers explain why so many Americans fail to receive routine CRC screening. Patients report a lack of knowledge about the need for screening or their screening options, and many view screening as messy, uncomfortable, or e ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Addressing bone marrow lesions that compromise osteochondral tissue repair

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    ABSTRACT Degenerative joint diseases such as osteoarthritis (OA) remain the source of significant pain and disability, affecting over 30 million adults with an annual US economic burden of more than $486 billion. Joint replacement is a well-established procedure, but its finite life span makes this treatment unacceptable for younger (under 65) or more active individuals. For this growing patient p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. A Global Test of Hemostatic Risk

    SBC: Haematologic Technologies, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Although the vast majority of patients who suffer from venous or arterial thrombosis have haemostatic systems that fall within the "normal" range of routine screening tools such as PT, aPTT, and factor assays, thrombosis is the major cause of death in Western countries. In contrast, the propensity to bleed (i.e., hemophilia) is more easily diagnosed by traditio ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  7. A Global Test of Hemostatic Risk

    SBC: Haematologic Technologies, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Phase I funding for this project supported successful studies that were aimed at demonstrating the feasibility of developing an easy to use, global test in the arena of clinical hemostasis that would be sensitive to antithrombotic drugs, bleeding disorders and thrombotic pathologies. This test comprises a measurement of the rate of thrombin generation and/or to ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  8. Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis

    SBC: Generx+, Inc.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The investigators have developed a plasmid vector that expresses the normal human alpha-1 antitrypsin (AAT) gene in human respiratory epithelium when delivered as a plasmid-cationic liposome complex. In subjects with inherited AAT deficiency, they showed that liposome mediated transfer of the normal AAT gene to the nasal respiratory epi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy

    SBC: Praetego Inc            Topic: NEI

    PROJECT SUMMARY Diabetic Retinopathy (DR) is a serious diabetic complication that is the leading cause of vision loss in working- age adults, affecting more than 7.5 million people in the USA. It causes more new cases of blindness than any other eye disease in people between the ages of 18 and 65. The anti-VEGF treatments can slow the progress of DR in many patients but are only used after signifi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. AML MutationCounter a tool to detect residual and recurrent leukemia

    SBC: Asystbio Laboratories, LLC            Topic: 102

    Abstract AsystBio LLC proposes to market a molecular tool kit called AML MutationCounter to count somatic mutations in genes that contribute to the development of acute myeloid leukemia AML We have developed a set of reagents and computer programs for application of next generation sequencing to count AML gene mutations The tool kit is versatile and can be used with either of the two major DNA ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government